On November 14, 2024, bluebird bio, Inc. reported its financial results for the third quarter ended September 30, 2024. The company announced a net revenue of $10.6 million for the quarter, with an anticipated increase to at least $25 million in the fourth quarter. The report highlighted the completion or scheduling of 74 patient starts in 2024 across bluebird bio's commercial portfolio. CEO Andrew Obenshain noted the doubling of patient starts from the second to third quarter, reflecting the acceleration of commercial launches. The company is focused on securing additional cash resources to extend its runway and achieve cash flow break-even in the second half of 2025. Commercial updates included 57 patient starts completed in 2024, with 17 additional starts scheduled for the remainder of the year. Over 70 Qualified Treatment...Show More

On November 14, 2024, bluebird bio, Inc. reported its financial results for the third quarter ended September 30, 2024. The company announced a net revenue of $10.6 million for the quarter, with an anticipated increase to at least $25 million in the fourth quarter. The report highlighted the completion or scheduling of 74 patient starts in 2024 across bluebird bio's commercial portfolio. CEO Andrew Obenshain noted the doubling of patient starts from the second to third quarter, reflecting the acceleration of commercial launches. The company is focused on securing additional cash resources to extend its runway and achieve cash flow break-even in the second half of 2025. Commercial updates included 57 patient starts completed in 2024, with 17 additional starts scheduled for the remainder of the year. Over 70 Qualified Treatment Centers (QTCs) have been activated, with 40% having initiated or completed treatment for at least one patient. The company also reported on favorable coverage for LYFGENIA, with more than half of all states affirming coverage and nearly 50% of Medicaid-insured individuals with sickle cell disease living in states that have completed prior authorization approval. bluebird bio will present updated data from its gene therapy programs at the 66th American Society of Hematology (ASH) Annual Meeting in December 2024. Financially, the company's cash position was approximately $118.7 million as of September 30, 2024. Total revenue for the third quarter was slightly down from the same period in 2023, with a net loss of $60.8 million, an improvement from the net loss of $87.2 million in the previous year. The company's cost-saving initiatives and renegotiation of key contracts are expected to contribute to the anticipated cash flow break-even.